# EDGAR Filing Document

**Accession Number:** 0001835579
**File Stem:** 0001193125-26-110945
**Filing Date:** 2026-3
**Character Count:** 6344
**Document Hash:** 994bc6b80081635be7b89c1ac966e8d7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-110945.hdr.sgml**: 20260317

**ACCESSION NUMBER**: 0001193125-26-110945

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260312

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20260317

**DATE AS OF CHANGE**: 20260317

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ImageneBio, Inc.
- **CENTRAL INDEX KEY:** 0001835579
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811697316
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40287
- **FILM NUMBER:** 26762509

**BUSINESS ADDRESS:**
- **STREET 1:** 12526 HIGH BLUFF DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** 857-343-8292

**MAIL ADDRESS:**
- **STREET 1:** 12526 HIGH BLUFF DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ikena Oncology, Inc.
- **DATE OF NAME CHANGE:** 20201208

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 OR 15(d)

#### of The Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): March 12, 2026

## IMAGENEBIO, INC.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40287** | **81-1697316** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **12526 High Bluff Drive, Suite 345** |  |
| **San Diego, California** | **92130** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

#### Registrant's telephone number, including area code: (858) 345-6265

#### Not Applicable

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange**<br> **on which registered** |
| Common Stock, $0.001 par value IMA | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**  |

---

On March 12, 2026, ImageneBio, Inc. (the "Company") and Erin Butler, the Company's Senior Vice President, Finance & Administration and Principal Accounting Officer, agreed to a mutual separation effective March 20, 2026 (the "Butler Separation Date"). Effective as of the Butler Separation Date, Ms. Butler will no longer serve as the Company's Principal Accounting Officer.

The Company expects to enter into a separation agreement (the "Separation Agreement") with Ms. Butler, pursuant to which Ms. Butler will receive the severance benefits set forth in her Severance Rights Agreement, dated October 21, 2024 and filed as Exhibit 10.16 to the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on July 29, 2025.

The Company's board of directors has, effective as of the Butler Separation Date, appointed Bob Lally, our Senior Vice President, Finance & Operations, as the Company's Principal Accounting Officer.

Bob Lally, age 63, has served as our Senior Vice President, Finance & Operations since July 2025. Previously, Mr. Lally served as Senior Vice President, Finance & Operations at our predecessor, Ikena Oncology, Inc. from December 2022 to July 2025. Mr. Lally served in various roles of increasing responsibility at Prevail Therapeutics Inc. where he served as Vice President, Finance from February 2019 through March 2021 and as Chief Operating Officer from March 2021 through June 2022. Prior to that, Mr. Lally served as Executive Director, Finance and Controller at Arsanis, Inc. from May 2016 through March 2019. Mr. Lally holds a B.S. in finance from the University of Massachusetts, Lowell.

Mr. Lally did not enter into any material plan, contract or arrangement with the Company in connection with his appointment as the Company's principal accounting officer.

There are no family relationships between Mr. Lally and any of the Company's current or former directors or executive officers. Mr. Lally is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Act of 1933, as amended.

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **IMAGENEBIO, INC.** | **IMAGENEBIO, INC.** |
| Date: March 17, 2026 | By: | /s/ Kristin Yarema |
|  |  | Kristin Yarema, Ph.D. |
|  |  | Chief Executive Officer |

---